It has been shown that the use of inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) can reduce NAD+ levels by inhibiting energy metabolism pathways like glycolysis, citric acid cycle and oxidative phosphorylation (OXPHOS), contributing to a decrease in cancer proliferation [45]. Here, NAMPT is linked to cancer.